Migraine and possible facial variants (neurovascular orofacial pain)

Orofacial Pain and Headache

Volumn , Issue , 2008, Pages 193-224

  Sharav, Yair ^a   Benoliel, Rafael ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882548569     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7234-3412-2.10009-4     Document Type: Chapter

References (287)

1. SK Afridi, NJ Giffin, H Kaube, et al. (2005) A positron emission tomographic study in spontaneous migraine. Arch Neurol 62(8), 1270-1275.
2. SK Afridi, MS Matharu, L Lee, et al. (2005) A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128(Pt 4), 932-939.
3. KB Alstadhaug, R Salvesen and SI Bekkelund (2005) Seasonal variation in migraine. Cephalalgia 25(10), 811-816.
4. M Ashina, H Simonsen, L Bendtsen, et al. (2004) Glyceryl trinitrate may trigger endogenous nitric oxide production in patients with chronic tension-type headache. Cephalalgia 24(11), 967-972.
5. L Baandrup and R Jensen (2005) Chronic post-traumatic headache-a clinical analysis in relation to the International Headache Classification 2nd Edition. Cephalalgia 25(2), 132-138.
6. A Bahra, MS Matharu, C Buchel, et al. (2001) Brainstem activation specific to migraine headache. Lancet 357(9261), 1016-1017.
7. P Barbanti, G Fabbrini, M Pesare, et al. (2002) Unilateral cranial autonomic symptoms in migraine. Cephalalgia 22(4), 256-259.
8. T Bartsch, YE Knight and PJ Goadsby (2004) Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 56(3), 371-381.
9. R Benoliel, H Elishoov and Y Sharav (1997) Orofacial pain with vascular-type features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84(5), 506-512.
10. R Benoliel, N Birman, E Eliav, et al. (2008) The International Headache Society classification: accurate diagnosis of orofacial pain? Cephalalgia [in press]
11. B Bille (1997) A 40-year follow-up of school children with migraine. Cephalalgia 17(4), 488-491. discussion 487
12. H Bolay, U Reuter, AK Dunn, et al. (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8(2), 136-142.
13. P Bonaventure, P Voorn, WH Luyten, et al. (1998) 5HT1B and 5HT1D receptor mRNA differential co-localization with peptide mRNA in the guinea pig trigeminal ganglion. Neuroreport 9(4), 641-645.
14. I Bouchelet, Z Cohen, B Case, et al. (1996) Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 50(2), 219-223.
15. N Breslau and BK Rasmussen (2001) The impact of migraine: epidemiology, risk factors, and co-morbidities. Neurology 56(6 Suppl 1), S4-S12.
16. N Breslau, GC Davis and P Andreski (1991) Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. Psychiatry Res 37(1), 11-23.
17. S Bulut, MS Berilgen, A Baran, et al. (2004) Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 107(1), 44-48.
18. R Burstein, MF Cutrer and D Yarnitsky (2000) The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123(Pt 8), 1703-1709.
19. R Burstein, B Collins and M Jakubowski (2004) Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 55(1), 19-26.
20. G Bussone and V Tullo (2005) Reflections on the nosology of cranio-facial pain syndromes. Neurol Sci 26(Suppl 2), S61-S64.
21. MG Buzzi and MA Moskowitz (1991) Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 11(4), 165-168.
22. MG Buzzi, WB Carter, T Shimizu, et al. (1991) Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30(11), 1193-1200.
23. MR Byers and MV Narhi (1999) Dental injury models: experimental tools for understanding neuroinflammatory interactions and polymodal nociceptor functions. Crit Rev Oral Biol Med 10(1), 4-39.
24. R Cady, C Schreiber, K Farmer, et al. (2002) Primary headaches: a convergence hypothesis. Headache 42(3), 204-216.
25. JK Campbell and F Sakai (2000) The migraines; diagnosis and differential diagnosis. J Olesen, P Tfelt-Hansen, KMA Welch (Eds) The Headaches 2nd edn. Philadelphia: Lippincott Williams and Wilkins
26. JK Campbell, J Keith, DB Penzien, et al. (2000) US Headache Consortium: Evidenced-Based Guidelines for Migraine Headache: Behavioral and Physical Treatments http://www.aan.com/professionals/practice/pdfs/gl0089.pdf October 2005 Available at
27. Y Cao, SK Aurora, V Nagesh, et al. (2002) Functional MRI-BOLD of brainstem structures during visually triggered migraine. Neurology 59(1), 72-78.
28. A Cavallini, G Micieli, G Bussone, et al. (1995) Headache and quality of life. Headache 35(1), 29-35.
29. I Ceccarelli, P Fiorenzani, G Grasso, et al. (2004) Estrogen and mu-opioid receptor antagonists counteract the 17 beta-estradiol-induced licking increase and interferon-gamma reduction occurring during the formalin test in male rats. Pain 111(1–2), 181-190.
30. Centers for Disease Control (1991) Current Trends Prevalence of Chronic Migraine Headaches - United States, 1980–1989. Morbidity and Mortality Weekly Report 40(20), 331. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001982.htm 337–338. Available at
31. H Chabriat, J Danchot, P Michel, et al. (1999) Precipitating factors of headache. A prospective study in a national control-matched survey in migraineurs and nonmigraineurs. Headache 39(5), 335-338.
32. E Chronicle and W Mulleners (2004) Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev (3), CD003226
33. GL Cohen (2005) Migraine prophylactic drugs work via ion channels. Med Hypotheses 65(1), 114-122.
34. D Cologno, P Torelli and GC Manzoni (1998) Migraine with aura: a review of 81 patients at 10-20 years' follow-up. Cephalalgia 18(10), 690-696.
35. NJ Colson, RA Lea, S Quinlan, et al. (2004) The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. Neurogenetics 5(2), 129-133.
36. A Costa, S Ravaglia, G Sances, et al. (2003) Nitric oxide pathway and response to nitroglycerin in cluster headache patients: plasma nitrite and citrulline levels. Cephalalgia 23(6), 407-413.
37. JR Couch and C Bearss (2001) Chronic daily headache in the posttrauma syndrome: relation to extent of head injury. Headache 41(6), 559-564.
38. JR Couch and RS Hassanein (1979) Amitriptyline in migraine prophylaxis. Arch Neurol 36(11), 695-699.
39. EG Couturier, MA Bomhof, AK Neven, et al. (2003) Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 23(4), 302-308.
40. FM Cutrer, AG Sorensen, RM Weisskoff, et al. (1998) Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol 43(1), 25-31.
41. R Czerninsky, R Benoliel and Y Sharav (1999) Odontalgia in vascular orofacial pain. J Orofac Pain 13(3), 196-200.
42. CGH Dahlof (2002) Management of primary headaches: current and future aspects. MA Giamberardino (Eds) Pain—An Updated Review: Refresher Course Seattle: IASP Press 85-112.
43. C Dahlof (2003) Clinical applications of new therapeutic deliveries in migraine. Neurology 61(8 Suppl 4), S31-S34.
44. CG Dahlof and N Mathew (1998) Cardiovascular safety of 5HT1B/1D agonists-is there a cause for concern? Cephalalgia 18(8), 539-545.
45. C Dahlof, K Ekbom and L Persson (1994) Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache. Arch Neurol 51(12), 1256-1261.
46. CG Dahlof, AM Rapoport, FD Sheftell, et al. (1999) Rizatriptan in the treatment of migraine. Clin Ther 21(11), 1823-1836. discussion 1821
47. CG Dahlof, D Dodick, AJ Dowson, et al. (2002) How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache 42(2), 99-113.
48. D D'Amico, A Ferraris, M Leone, et al. (2002) Increased plasma nitrites in migraine and cluster headache patients in interictal period: basal hyperactivity of L-arginine-NO pathway? Cephalalgia 22(1), 33-36.
49. AT Daudia and NS Jones (2002) Facial migraine in a rhinological setting. Clin Otolaryngol Allied Sci 27(6), 521-525.
50. M De Fusco, R Marconi, L Silvestri, et al. (2003) Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 33(2), 192-196.
51. M Diamond and R Cady (2005) Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care. Am J Med 118(Suppl 1), 18S-27S.
52. S Diamond, L Kudrow, J Stevens, et al. (1982) Long-term study of propranolol in the treatment of migraine. Headache 22(6), 268-271.
53. HC Diener (2003) RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 23(3), 183-185.
54. H Diener, V Pfaffenrath, L Pageler, et al. (2005) The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 25(10), 776-787.
55. DW Dodick, TD Rozen, PJ Goadsby, et al. (2000) Cluster headache. Cephalalgia 20(9), 787-803.
56. DW Dodick, EJ Eross, JM Parish, et al. (2003) Clinical, anatomical, and physiologic relationship between sleep and headache. Headache 43(3), 282-292.
57. DW Dodick, RB Lipton, MD Ferrari, et al. (2004) Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project. Curr Pain Headache Rep 8(6), 435-442.
58. D Dodick, J Brandes, A Elkind, et al. (2005) Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs 19(2), 125-136.
59. ME Drake Jr, NI Greathouse, JB Renner, et al. (2004) Open-label zonisamide for refractory migraine. Clin Neuropharmacol 27(6), 278-280.
60. PD Drummond, A Gonski and JW Lance (1983) Facial flushing after thermocoagulation of the Gasserian ganglion. J Neurol Neurosurg Psychiatry 46(7), 611-616.
61. A Ducros, A Joutel, K Vahedi, et al. (1997) Mapping of a second locus for familial hemiplegic migraine to 1q21-q23 and evidence of further heterogeneity. Ann Neurol 42(6), 885-890.
62. MK Eriksen, LL Thomsen and MB Russell (2004) Prognosis of migraine with aura. Cephalalgia 24(1), 18-22.
63. M Estevez and KL Gardner (2004) Update on the genetics of migraine. Hum Genet 114(3), 225-235.
64. S Evers, J Vollmer-Haase, S Schwaag, et al. (2004) Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 24(10), 838-843.
65. A Fazekas, K Vindisch, E Posch, et al. (1990) Experimentally-induced neurogenic inflammation in the rat oral mucosa. J Periodontal Res 25(5), 276-282.
66. A Fazekas, A Gyorfi, F Irmes, et al. (1992) Effect of substance P administration on vascular permeability in the rat dental pulp and submandibular gland. Proc Finn Dent Soc 88(Suppl 1), 481-486.
67. MD Ferrari (2003) Current perspectives on effective migraine treatments: are small clinical differences important for patients? Drugs Today (Barc) 39(Suppl D), 37-41.
68. MD Ferrari and MB Russell (2000) Genetics of migraine. J Olesen, P Tfelt-Hansen, KMA Welch (Eds) The Headaches 2nd edn. Philadelphia: Lippincott Williams and Wilkins 241-254.
69. MD Ferrari, KI Roon, RB Lipton, et al. (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294), 1668-1675.
70. MD Ferrari, PJ Goadsby, KI Roon, et al. (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22(8), 633-658.
71. B Forssman, CJ Lindblad and V Zbornikova (1983) Atenolol for migraine prophylaxis. Headache 23(4), 188-190.
72. AW Fox and RL Davis (1998) Migraine chronobiology. Headache 38(6), 436-441.
73. AW Fox, ML Diamond and EL Spierings (2005) Migraine during pregnancy: options for therapy. CNS Drugs 19(6), 465-481.
74. FG Freitag, S Diamond, ML Diamond, et al. (2001) Divalproex in the long-term treatment of chronic daily headache. Headache 41(3), 271-278.
75. JL Fuh, SJ Wang, SR Lu, et al. (2003) Ice-cream headache-a large survey of 8359 adolescents. Cephalalgia 23(10), 977-981.
76. M Gervil, V Ulrich, J Kaprio, et al. (1999) The relative role of genetic and environmental factors in migraine without aura. Neurology 53(5), 995-999.
77. CM Gibb, PT Davies, V Glover, et al. (1991) Chocolate is a migraine-provoking agent. Cephalalgia 11(2), 93-95.
78. NJ Giffin, L Ruggiero, RB Lipton, et al. (2003) Premonitory symptoms in migraine: an electronic diary study. Neurology 60(6), 935-940.
79. PJ Goadsby (2001) Neuroimaging in headache. Microsc Res Tech 53(3), 179-187.
80. PJ Goadsby (2002) Neurovascular headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine. Cephalalgia 22(2), 107-111.
81. PJ Goadsby (2005) Migraine pathophysiology. Headache 45(Suppl 1), S14-S24.
82. PJ Goadsby (2005) New targets in the acute treatment of headache. Curr Opin Neurol 18(3), 283-288.
83. PJ Goadsby (2005) Advances in the understanding of headache. Br Med Bull 73–74 83-92.
84. PJ Goadsby and JD Classey (2003) Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 122(2), 491-498.
85. PJ Goadsby and L Edvinsson (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1), 48-56.
86. PJ Goadsby and L Edvinsson (1994) Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 117(Pt 3), 427-434.
87. PJ Goadsby and L Edvinsson (1996) Neuropeptide changes in a case of chronic paroxysmal hemicrania-evidence for trigemino-parasympathetic activation. Cephalalgia 16(6), 448-450.
88. PJ Goadsby and KL Hoskin (1997) The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat 190(Pt 3), 367-375.
89. PJ Goadsby, GA Lambert and JW Lance (1986) Stimulation of the trigeminal ganglion increases flow in the extracerebral but not the cerebral circulation of the monkey. Brain Res 381(1), 63-67.
90. PJ Goadsby, L Edvinsson and R Ekman (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23(2), 193-196.
91. PJ Goadsby, L Edvinsson and R Ekman (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23(2), 193-196.
92. PJ Goadsby, AS Zagami and GA Lambert (1991) Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 31(6), 365-371.
93. PJ Goadsby, RB Lipton and MD Ferrari (2002) Migraine—current understanding and treatment. N Engl J Med 346(4), 257-270.
94. R Goder, G Fritzer, A Kapsokalyvas, et al. (2001) Polysomnographic findings in nights preceding a migraine attack. Cephalalgia 21(1), 31-37.
95. J Goldstein, SD Silberstein, JR Saper, et al. (2005) Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache 45(8), 973-982.
96. JD Gomersall and A Stuart (1973) Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 36(4), 684-690.
97. F Granella, G Sances, E Pucci, et al. (2000) Migraine with aura and reproductive life events: a case control study. Cephalalgia 20(8), 701-707.
98. F Granella, G Sances, G Allais, et al. (2004) Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 24(9), 707-716.
99. A Gyorfi, A Fazekas, F Irmes, et al. (1995) Effect of substance P administration on vascular permeability in the rat oral mucosa and sublingual gland. J Periodontal Res 30(3), 181-185.
100. DC Haas, PF Kent and DI Friedman (1993) Headache caused by a single lesion of multiple sclerosis in the periaqueductal gray area. Headache 33(8), 452-455.
101. N Hadjikhani, M Sanchez Del Rio, O Wu, et al. (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 98(8), 4687-4692.
102. P Henry, P Michel, B Brochet, et al. (1992) A nationwide survey of migraine in France: prevalence and clinical features in adults. GRIM. Cephalalgia 12(4), 229-237. discussion 186
103. KJ Heyeraas and I Kvinnsland (1992) Tissue pressure and blood flow in pulpal inflammation. Proc Finn Dent Soc 88(Suppl 1), 393-401.
104. KA Holroyd, DB Penzien and GE Cordingley (1991) Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 31(5), 333-340.
105. KL Hoskin, DC Bulmer and PJ Goadsby (1999) Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci Lett 266(3), 173-176.
106. KL Hoskin, AS Zagami and PJ Goadsby (1999) Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat 194(Pt 4), 579-588.
107. T Iijima and JQ Zhang (2002) Three-dimensional wall structure and the innervation of dental pulp blood vessels. Microsc Res Tech 56(1), 32-41.
108. R Inoki, T Toyoda and I Yamamoto (1973) Elaboration of a bradykinin-like substance in dog's canine pulp during electrical stimulation and its inhibition by narcotic and nonnarcotic analgesics. Naunyn Schmiedebergs Arch Pharmacol 279(4), 387-398.
109. HK Iversen, M Langemark, PG Andersson, et al. (1990) Clinical characteristics of migraine and episodic tension-type headache in relation to old and new diagnostic criteria. Headache 30(8), 514-519.
110. H Izumi (1999) Nervous control of blood flow in the orofacial region. Pharmacol Ther 81(2), 141-161.
111. H Izumi and K Karita (1991) Vasodilator responses following intracranial stimulation of the trigeminal, facial and glossopharyngeal nerves in the cat gingiva. Brain Res 560(1–2), 71-75.
112. KW Jones, MG Ehm, MA Pericak-Vance, et al. (2001) Migraine with aura susceptibility locus on chromosome 19p13 is distinct from the familial hemiplegic migraine locus. Genomics 78(3), 150-154.
113. A Joutel, MG Bousser, V Biousse, et al. (1993) A gene for familial hemiplegic migraine maps to chromosome 19. Nat Genet 5(1), 40-45.
114. G Juhasz, T Zsombok, EA Modos, et al. (2003) NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106(3), 461-470.
115. M Kallela, M Wessman, M Farkkila, et al. (1999) Clinical characteristics of migraine in a population-based twin sample: similarities and differences between migraine with and without aura. Cephalalgia 19(3), 151-158.
116. RG Kaniecki (1997) A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 54(9), 1141-1145.
117. N Karli, M Zarifoglu, N Calisir, et al. (2005) Comparison of pre-headache phases and trigger factors of migraine and episodic tension-type headache: do they share similar clinical pathophysiology? Cephalalgia 25(6), 444-451.
118. Z Katsarava, S Schneeweiss, T Kurth, et al. (2004) Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62(5), 788-790.
119. H Kaube, KA Keay, KL Hoskin, et al. (1993) Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res 629(1), 95-102.
120. H Kaube, KL Hoskin and PJ Goadsby (1993) Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 109(3), 788-792.
121. AO Kaup, NT Mathew, C Levyman, et al. (2003) ‘Side locked’ migraine and trigeminal autonomic cephalgias: evidence for clinical overlap. Cephalalgia 23(1), 43-49.
122. L Kelman (2004) The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache 44(9), 865-872.
123. L Kelman (2004) The aura: a tertiary care study of 952 migraine patients. Cephalalgia 24(9), 728-734.
124. L Kelman (2005) Migraine pain location: a tertiary care study of 1283 migraineurs. Headache 45(8), 1038-1047.
125. L Kelman and JC Rains (2005) Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache 45(7), 904-910.
126. S Kim (1990) Neurovascular interactions in the dental pulp in health and inflammation. J Endod 16(2), 48-53.
127. J Klapper (1997) Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 17(2), 103-108.
128. YE Knight and PJ Goadsby (2001) The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience 106(4), 793-800.
129. YE Knight, T Bartsch, H Kaube, et al. (2002) P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 22(5), RC213
130. YE Knight, JD Classey, MP Lasalandra, et al. (2005) Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious craniovascular stimulation and periaqueductal gray stimulation in the cat. Brain Res 1045(1–2), 1-11.
131. RC Komorowski, CD Torneck and JW Hu (1996) Neurogenic inflammation and tooth pulp innervation pattern in sympathectomized rats. J Endod 22(8), 414-417.
132. E Koseoglu, M Nacar, A Talaslioglu, et al. (2003) Epidemiological and clinical characteristics of migraine and tension type headache in 1146 females in Kayseri, Turkey. Cephalalgia 23(5), 381-388.
133. C Kruuse, LL Thomsen, S Birk, et al. (2003) Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126(Pt 1), 241-247.
134. AV Krymchantowski and PF Moreira (2001) Clinical presentation of transformed migraine: possible differences among male and female patients. Cephalalgia 21(5), 558-566.
135. GA Lambert, N Bogduk, PJ Goadsby, et al. (1984) Decreased carotid arterial resistance in cats in response to trigeminal stimulation. J Neurosurg 61(2), 307-315.
136. JW Lance and PJ Goadsby (2005) Mechanism and management of headache 7th edn. Elsevier: Philadelphia
137. LH Lassen, M Ashina, I Christiansen, et al. (1997) Nitric oxide synthase inhibition in migraine. Lancet 349(9049), 401-402.
138. LH Lassen, PA Haderslev, VB Jacobsen, et al. (2002) CGRP may play a causative role in migraine. Cephalalgia 22(1), 54-61.
139. M Leone and G Bussone (1993) A review of hormonal findings in cluster headache. Evidence for hypothalamic involvement. Cephalalgia 13(5), 309-317.
140. D Lewis, S Ashwal, A Hershey, et al. (2004) Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 63(12), 2215-2224.
141. PJ Lewis, SF Barrington, PK Marsden, et al. (1997) A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography. Neurology 48(6), 1542-1550.
142. K Linde and K Rossnagel (2004) Propranolol for migraine prophylaxis. Cochrane Database Syst Rev (2), CD003225
143. RB Lipton and ME Bigal (2005) Migraine: epidemiology, impact, and risk factors for progression. Headache 45(Suppl 1), S3-S13.
144. RB Lipton and J Pan (2004) Is migraine a progressive brain disease? JAMA 291(4), 493-494.
145. RB Lipton, WF Stewart, AM Stone, et al. (2000) Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 284(20), 2599-2605.
146. RB Lipton, WF Stewart and AI Scher (2000) Epidemiology of migraine. HC Diener (Eds) Treatment of Migraine and Other Headaches Basel: Karger 2-15.
147. RB Lipton, WF Stewart, S Diamond, et al. (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41(7), 646-657.
148. RB Lipton, S Diamond, M Reed, et al. (2001) Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41(7), 638-645.
149. RB Lipton, AI Scher, K Kolodner, et al. (2002) Migraine in the United States: epidemiology and patterns of health care use. Neurology 58(6), 885-894.
150. E Loder (2005) Fixed drug combinations for the acute treatment of migraine: place in therapy. CNS Drugs 19(9), 769-784.
151. E Loder and D Biondi (2005) General principles of migraine management: the changing role of prevention. Headache 45(Suppl 1), S33-S47.
152. AC Lyngberg, BK Rasmussen, T Jorgensen, et al. (2005) Incidence of primary headache: a Danish epidemiologic follow-up study. Am J Epidemiol 161(11), 1066-1073.
153. QP Ma (2001) Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport 12(8), 1589-1591.
154. QP Ma, R Hill and D Sirinathsinghji (2001) Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Eur J Neurosci 13(11), 2099-2104.
155. EA MacGregor, J Brandes and A Eikermann (2003) Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. Headache 43(1), 19-26.
156. EA MacGregor, J Brandes, A Eikermann, et al. (2004) Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey-Phase III. Curr Med Res Opin 20(7), 1143-1150.
157. JE Magnusson and WJ Becker (2003) Migraine frequency and intensity: relationship with disability and psychological factors. Headache 43(10), 1049-1059.
158. DA Marcus, L Scharff, D Turk, et al. (1997) A double-blind provocative study of chocolate as a trigger of headache. Cephalalgia 17(8), 855-862. discussion 800
159. VT Martin and MM Behbehani (2001) Toward a rational understanding of migraine trigger factors. Med Clin North Am 85(4), 911-941.
160. VT Martin, S Wernke, K Mandell, et al. (2005) Defining the relationship between ovarian hormones and migraine headache. Headache 45(9), 1190-1201.
161. DB Matchar, WB Young, JH Rosenberg, et al. (2000) US Headache Consortium: Evidence-Based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management of Acute Attacks http://www.aan.com/professionals/practice/pdfs/gl0087.pdf October 2005 American Academy of Neurology. Available at
162. MS Matharu, CD Good, A May, et al. (2003) No change in the structure of the brain in migraine: a voxel-based morphometric study. Eur J Neurol 10(1), 53-57.
163. MS Matharu, T Bartsch, N Ward, et al. (2004) Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 127(Pt 1), 220-230.
164. NT Mathew (1981) Prophylaxis of migraine and mixed headache. A randomized controlled study. Headache 21(3), 105-109.
165. NT Mathew, U Reuveni and F Perez (1987) Transformed or evolutive migraine. Headache 27(2), 102-106.
166. P Mattsson, K Svardsudd, PO Lundberg, et al. (2000) The prevalence of migraine in women aged 40-74 years: a population-based study. Cephalalgia 20(10), 893-899.
167. A May and PJ Goadsby (1999) The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 19(2), 115-127.
168. A May, A Bahra, C Buchel, et al. (1998) Hypothalamic activation in cluster headache attacks. Lancet 352(9124), 275-278.
169. A May, H Kaube, C Buchel, et al. (1998) Experimental cranial pain elicited by capsaicin: a PET study. Pain 74(1), 61-66.
170. A May, J Ashburner, C Buchel, et al. (1999) Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat Med 5(7), 836-838.
171. A May, A Bahra, C Buchel, et al. (2000) PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 55(9), 1328-1335.
172. A May, C Buchel, R Turner, et al. (2001) Magnetic resonance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation. J Cereb Blood Flow Metab 21(10), 1171-1176.
173. KR Merikangas and BK Rasmussen (2000) Migraine comorbidity. J Olesen, P Tfelt-Hansen, KMA Welch (Eds) The Headaches 2nd edn. Philadelphia: Lippincott Williams and Wilkins 235-240.
174. H Merskey and N Bogduk (1994) Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definition of Pain Terms 2nd edn. Seattle: IASP Press
175. GS Miller (2004) Efficacy and safety of levetiracetam in pediatric migraine. Headache 44(3), 238-243.
176. DS Millson, SJ Tepper and AM Rapoport (2000) Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother 1(3), 391-404.
177. M Mochi, S Cevoli, P Cortelli, et al. (2003) A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-beta-hydroxylase genes. Neurol Sci 23(6), 301-305.
178. A Moore, J Edwards, J Barden, et al. (2003) Bandolier's Little Book of Pain Oxford: Oxford University Press
179. SS Morey (2000) Guidelines on migraine: part 5. Recommendations for specific prophylactic drugs. Am Fam Physician 62(11), 2535-2539.
180. LE Morillo (2004) Migraine headache. Clin Evid (11), 1696-1719.
181. MA Moskowitz (1990) Basic mechanisms in vascular headache. Neurol Clin 8(4), 801-815.
182. MA Moskowitz and FM Cutrer (1993) SUMATRIPTAN: a receptor-targeted treatment for migraine. Annu Rev Med 44 145-154.
183. MA Moskowitz, K Nozaki and RP Kraig (1993) Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 13(3), 1167-1177.
184. RS Murthy, JM Bertolote, J Epping-Jordan, et al. (2001) The World Health Report 2001. Mental health: new understanding, new hope Geneva: WHO Library
185. K Nozaki, P Boccalini and MA Moskowitz (1992) Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space. Neuroscience 49(3), 669-680.
186. B O'Brien, R Goeree and D Streiner (1994) Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol 23(5), 1020-1026.
187. T Ohkubo, M Shibata, Y Yamada, et al. (1993) Role of substance P in neurogenic inflammation in the rat incisor pulp and the lower lip. Arch Oral Biol 38(2), 151-158.
188. JP Okeson (2005) Vascular and neurovascular pains. JP Okeson (Eds) Bell's Orofacial Pains 6th edn. Chicago: Quintessence Publishing 401-448.
189. J Olesen (2000) The migraines: introduction. J Olesen, P Tfelt-Hansen, KMA Welch (Eds) The Headaches 2nd edn. Philadelphia: Lippincott Williams & Wilkins 223-225.
190. J Olesen and FM Cutrer (2000) Migraine with aura and its subforms. J Olesen, P Tfelt-Hansen, KMA Welch (Eds) The Headaches 2nd edn. Philadelphia: Lippincott Williams & Wilkins 345-363.
191. J Olesen, M-G Bousser, HC Diener, et al. (2004) The International Classification of Headache Disorders, 2nd Edition. Cephalalgia 24(suppl 1), 24-150.
192. J Olesen, HC Diener, IW Husstedt, et al. (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350(11), 1104-1110.
193. RA Ophoff, R van Eijk, LA Sandkuijl, et al. (1994) Genetic heterogeneity of familial hemiplegic migraine. Genomics 22(1), 21-26.
194. RA Ophoff, GM Terwindt, MN Vergouwe, et al. (1996) Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87(3), 543-552.
195. J Pascual, R Leira and JM Lainez (2003) Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 23(10), 961-962.
196. RC Peatfield (1995) Relationships between food, wine, and beer-precipitated migrainous headaches. Headache 35(6), 355-357.
197. M Peñarrocha, A Bandres, M Penarrocha, et al. (2004) Lower-half facial migraine: a report of 11 cases. J Oral Maxillofac Surg 62(12), 1453-1456.
198. MF Peres, M Sanchez del Rio, ML Seabra, et al. (2001) Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 71(6), 747-751.
199. BF Perry, IS Login and SE Kountakis (2004) Nonrhinologic headache in a tertiary rhinology practice. Otolaryngol Head Neck Surg 130(4), 449-452.
200. W Pryse-Phillips, H Findlay, P Tugwell, et al. (1992) A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci 19(3), 333-339.
201. WE Pryse-Phillips, DW Dodick, JG Edmeads, et al. (1998) Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ 159(1), 47-54.
202. V Puri, L Cui, CS Liverman, et al. (2005) Ovarian steroids regulate neuropeptides in the trigeminal ganglion. Neuropeptides 39(4), 409-417.
203. GP Putnam, S O'Quinn, CP Bolden-Watson, et al. (1999) Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia 19(7), 668-675.
204. JC Rains and JS Poceta (2005) Sleep-related headache syndromes. Semin Neurol 25(1), 69-80.
205. NM Ramadan (2004) Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 8(2), 91-95.
206. NM Ramadan, LL Schultz and SJ Gilkey (1997) Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 17(2), 73-80.
207. NM Ramadan, SD Silberstein, FG Freitag, et al. (October 2005) US Headache Consortium: Evidence-Based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management for Prevention of Migraine http://www.aan.com/professionals/practice/pdfs/gl0090.pdf American Academy of Neurology. Available at
208. NH Raskin, Y Hosobuchi and S Lamb (1987) Headache may arise from perturbation of brain. Headache 27(8), 416-420.
209. BK Rasmussen (1993) Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 53(1), 65-72.
210. BK Rasmussen (2001) Epidemiology of headache. Cephalalgia 21(7), 774-777.
211. BK Rasmussen and J Olesen (1992) Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 12(4), 221-228. discussion 186
212. BK Rasmussen and J Olesen (1992) Symptomatic and nonsymptomatic headaches in a general population. Neurology 42(6), 1225-1231.
213. BK Rasmussen, R Jensen and J Olesen (1991) A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia 11(3), 129-134.
214. BK Rasmussen, R Jensen, M Schroll, et al. (1991) Epidemiology of headache in a general population-a prevalence study. J Clin Epidemiol 44(11), 1147-1157.
215. GW Rebeck, KI Maynard, BT Hyman, et al. (1994) Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc Natl Acad Sci U S A 91(9), 3666-3669.
216. L Robbins (1994) Precipitating factors in migraine: a retrospective review of 494 patients. Headache 34(4), 214-216.
217. L Robbins (2002) Triptans versus analgesics. Headache 42(9), 903-907.
218. HD Rodd and FM Boissonade (2002) Comparative immunohistochemical analysis of the peptidergic innervation of human primary and permanent tooth pulp. Arch Oral Biol 47(5), 375-385.
219. JF Rothrock (1997) Successful treatment of persistent migraine aura with divalproex sodium. Neurology 48(1), 261-262.
220. MB Russell and J Olesen (1995) Increased familial risk and evidence of genetic factor in migraine. BMJ 311(7004), 541-544.
221. MB Russell and J Olesen (1996) A nosographic analysis of the migraine aura in a general population. Brain 119(Pt 2), 355-361.
222. MB Russell, BK Rasmussen, J Brennum, et al. (1992) Presentation of a new instrument: the diagnostic headache diary. Cephalalgia 12(6), 369-374.
223. MB Russell, BK Rasmussen, K Fenger, et al. (1996) Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia 16(4), 239-245.
224. MB Russell, V Ulrich, M Gervil, et al. (2002) Migraine without aura and migraine with aura are distinct disorders. A population-based twin survey. Headache 42(5), 332-336.
225. G Sances, F Granella, RE Nappi, et al. (2003) Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 23(3), 197-205.
226. G Sances, C Tassorelli, E Pucci, et al. (2004) Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia 24(2), 110-119.
227. M Sanchez del Rio, D Bakker, O Wu, et al. (1999) Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 19(8), 701-707.
228. JR Saper, D Dodick and JP Gladstone (2005) Management of chronic daily headache: challenges in clinical practice. Headache 45(Suppl 1), S74-S85.
229. L Savi, I Rainero, W Valfre, et al. (2002) Food and headache attacks. A comparison of patients with migraine and tension-type headache. Panminerva Med 44(1), 27-31.
230. AI Scher, WF Stewart, JA Ricci, et al. (2003) Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106(1–2), 81-89.
231. AI Scher, ME Bigal and RB Lipton (2005) Comorbidity of migraine. Curr Opin Neurol 18(3), 305-310.
232. RF Schnurr and RI Brooke (1992) Atypical odontalgia. Update and comment on long-term follow-up. O ral Surg Oral Med Oral Pathol 73(4), 445-448.
233. H Schon, DT Thomas, DA Jewkes, et al. (1987) Failure to detect plasma neuropeptide release during trigeminal thermocoagulation. J Neurol Neurosurg Psychiatry 50(5), 642-643.
234. M Sculpher, D Millson, D Meddis, et al. (2002) Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics 20(2), 91-100.
235. Y Sharav (1999) Orofacial pain. PD Wall, R Melzack (Eds) Textbook of Pain 4th edn. Edinburgh: Churchill Livingstone 711-738.
236. SD Silberstein (2000) Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55(6), 754-762.
237. SD Silberstein (2005) Preventive treatment of headaches. Curr Opin Neurol 18(3), 289-292.
238. SD Silberstein and PJ Goadsby (2002) Migraine: preventive treatment. Cephalalgia 22(7), 491-512.
239. SD Silberstein, PJ Goadsby and RB Lipton (2000) Management of migraine: an algorithmic approach. Neurology 55(9 Suppl 2), S46-S52.
240. SD Silberstein, JR Saper and FG Freitag (2001) Migraine: Diagnosis and treatment. SD Silberstein, RB Lipton, DJ Dalessio (Eds) Wolff's Headache and Other Head Pains 7th edn. Oxford: Oxford University Press 121-237.
241. M Silvestrini, M Bartolini, M Coccia, et al. (2003) Topiramate in the treatment of chronic migraine. Cephalalgia 23(8), 820-824.
242. GW Smetana (2000) The diagnostic value of historical features in primary headache syndromes: a comprehensive review. Arch Intern Med 160(18), 2729-2737.
243. TR Smith, A Sunshine, SR Stark, et al. (2005) Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 45(8), 983-991.
244. S Solomon, P Karfunkel and KM Guglielmo (1985) Migraine-cluster headache syndrome. Headache 25(5), 236-239.
245. S Solomon, RB Lipton and LC Newman (1992) Clinical features of chronic daily headache. Headache 32(7), 325-329.
246. EL Spierings, M Schroevers, PC Honkoop, et al. (1998) Presentation of chronic daily headache: a clinical study. Headache 38(3), 191-196.
247. EL Spierings, AH Ranke and PC Honkoop (2001) Precipitating and aggravating factors of migraine versus tension-type headache. Headache 41(6), 554-558.
248. PJ Spira and RG Beran (2003) Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 61(12), 1753-1759.
249. A Srikiatkhachorn and K Phanthumchinda (1997) Prevalence and clinical features of chronic daily headache in a headache clinic. Headache 37(5), 277-280.
250. PE Stang, PA Yanagihara, JW Swanson, et al. (1992) Incidence of migraine headache: a population-based study in Olmsted County, Minnesota. Neurology 42(9), 1657-1662.
251. TJ Steiner (2000) Headache burdens and bearers. Funct Neurol 15(Suppl 3), 219-223.
252. TJ Steiner, AI Scher, WF Stewart, et al. (2003) The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 23(7), 519-527.
253. WF Stewart, MS Linet, DD Celentano, et al. (1991) Age- and sex-specific incidence rates of migraine with and without visual aura. Am J Epidemiol 134(10), 1111-1120.
254. WF Stewart, RB Lipton, DD Celentano, et al. (1992) Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 267(1), 64-69.
255. WF Stewart, RB Lipton and J Liberman (1996) Variation in migraine prevalence by race. Neurology 47(1), 52-59.
256. WF Stewart, RB Lipton and D Simon (1996) Work-related disability: results from the American migraine study. Cephalalgia 16(4), 231-238. discussion 215
257. WF Stewart, J Staffa, RB Lipton, et al. (1997) Familial risk of migraine: a population-based study. Ann Neurol 41(2), 166-172.
258. WF Stewart, RB Lipton, KB Kolodner, et al. (2000) Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88(1), 41-52.
259. WF Stewart, RB Lipton and K Kolodner (2003) Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache 43(3), 258-265.
260. DL Stronks, JH Tulen, JB Bussmann, et al. (2004) Interictal daily functioning in migraine. Cephalalgia 24(4), 271-279.
261. J Tajti, S Moller, R Uddman, et al. (1999) The human superior cervical ganglion: neuropeptides and peptide receptors. Neurosci Lett 263(2–3), 121-124.
262. J Tajti, R Uddman, S Moller, et al. (1999) Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 76(2–3), 176-183.
263. S Tepper, C Allen, D Sanders, et al. (2003) Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache 43(1), 44-48.
264. SJ Tepper, ME Bigal, FD Sheftell, et al. (2004) Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache 44(8), 794-800.
265. P Tfelt-Hansen and J McEwen (2000) Nonsteroidal antiinflammatory drugs in the acute treatment of migraine. J Olesen, P Tfelt-Hansen, KMA Welch (Eds) The Headaches 2nd edn. Philadelphia: Lippincott Williams and Wilkins 391-397.
266. P Tfelt-Hansen and PR Saxena (2000) Ergot alkaloids in the acute treatment of migraine. J Olesen, P Tfelt-Hansen, KMA Welch (Eds) The Headaches 2nd edn. Philadelphia: Lippincott Williams and Wilkins 399-409.
267. P Tfelt-Hansen, P De Vries and PR Saxena (2000) Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60(6), 1259-1287.
268. LL Thomsen and J Olesen (2001) Nitric oxide in primary headaches. Curr Opin Neurol 14(3), 315-321.
269. GE Tomkins, JL Jackson, PG O'Malley, et al. (2001) Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 111(1), 54-63.
270. R Uddman, L Edvinsson, R Ekman, et al. (1985) Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 62(1), 131-136.
271. R Uddman, J Kato, P Lindgren, et al. (1999) Expression of calcitonin gene-related peptide-1 receptor mRNA in human tooth pulp and trigeminal ganglion. Arch Oral Biol 44(1), 1-6.
272. V Ulrich, M Gervil, KO Kyvik, et al. (1999) Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. Ann Neurol 45(2), 242-246.
273. KR Vanmolkot, EE Kors, JJ Hottenga, et al. (2003) Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol 54(3), 360-366.
274. F Veloso, K Kumar and C Toth (1998) Headache secondary to deep brain implantation. Headache 38(7), 507-515.
275. ER Vickers, MJ Cousins, S Walker, et al. (1998) Analysis of 50 patients with atypical odontalgia. A preliminary report on pharmacological procedures for diagnosis and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85(1), 24-32.
276. M Von Korff, WF Stewart, DJ Simon, et al. (1998) Migraine and reduced work performance: a population-based diary study. Neurology 50(6), 1741-1745.
277. C Waeber and MA Moskowitz (2003) Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology 61(8 Suppl 4), S9-S20.
278. C Weiller, A May, V Limmroth, et al. (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1(7), 658-660.
279. KM Welch (2003) Contemporary concepts of migraine pathogenesis. Neurology 61(8 Suppl 4), S2-S8.
280. KM Welch, NT Mathew, P Stone, et al. (2000) Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 20(8), 687-695.
281. KM Welch, V Nagesh, SK Aurora, et al. (2001) Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 41(7), 629-637.
282. WB Young, HC Siow and SD Silberstein (2004) Anticonvulsants in migraine. Curr Pain Headache Rep 8(3), 244-250.
283. AS Zagami and GA Lambert (1991) Craniovascular application of capsaicin activates nociceptive thalamic neurones in the cat. Neurosci Lett 121(1–2), 187-190.
284. AS Zagami and BK Rasmussen (2000) Symptomatology of migraine. J Olesen, P Tfelt-Hansen, KMA Welch (Eds) The Headaches 2nd edn. Philadelphia: Lippincott Williams and Wilkins 337-343.
285. K Zebenholzer, C Wober, C Kienbacher, et al. (2000) Migrainous disorder and headache of the tension-type not fulfilling the criteria: a follow-up study in children and adolescents. Cephalalgia 20(7), 611-616.
286. JA Zeller, V Lindner, K Frahm, et al. (2005) Platelet activation and platelet-leucocyte interaction in patients with migraine. Subtype differences and influence of triptans. Cephalalgia 25(7), 536-541.
287. DK Ziegler, A Hurwitz, RS Hassanein, et al. (1987) Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 44(5), 486-489.